Results 51 to 60 of about 6,491 (191)
Health Technology Assessment, 2008 Objectives: To systematically review the effectiveness and cost-effectiveness of palivizumab for the prevention of respiratory syncytial virus (RSV) in children and examine prognostic factors to determine whether subgroups can be identified with ...
D Wang +4 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2023 Palivizumab has been shown to decrease RSV-related hospitalization (RSVH) risk and reduce RSVH severity. American Academy of Pediatrics (AAP) guidance on administration of palivizumab has changed over time; in 2014, palivizumab was no longer recommended ...
Elizabeth R. Packnett +3 more
doaj +1 more source
Palivizumab: A debate about funding
Journal of Paediatrics and Child Health, 2010 AbstractA clinician and the chair of the hospital drug committee debate the merits of the use of palivizumab as prophylaxis against respiratory syncytial virus infection for a preterm baby with oxygen‐dependent, chronic lung disease and discuss the issue of public funding of palivizumab.
Fitzgerald, Dominic +2 more
openaire +3 more sources
The Medicaid Cost of Palivizumab [PDF]
Journal of the Pediatric Infectious Diseases Society, 2014 To the editor—Borse et al. [1] describe an economic analysis of respiratory syncytial virus (RSV) prophylaxis for infants in Alaska's Yukon-Kuskokwim Delta. The authors should be congratulated for evaluating this important question with a robust analysis. As these infants are almost entirely insured by Medicaid, we wish to clarify the net Medicaid cost
Ambrose, Christopher S. +1 more
openaire +1 more source
iNew Medicine, Volume 2, Issue 2, June 2026.This illustration integrates key concepts covered in the review, including high‐risk populations, viral structure, host entry factors, the replication cycle, and licensed antibody‐based prevention strategies. ABSTRACT Respiratory syncytial virus (RSV) is a negative‐sense RNA virus belonging to the genus Orthopneumovirus within the family Pneumoviridae.
Zekai Cheng +3 more
wiley +1 more source
Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals [PDF]
, 2022 Objectives: Palivizumab is a monoclonal antibody which can prevent infection with respiratory syncytial virus (RSV). Due to its high cost, it is recommended for high-risk infants only.
Standing, JF +7 more
core +1 more source
Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants
Pediatric Pulmonology, Volume 61, Issue 6, June 2026.ABSTRACT Introduction Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and hospitalization in infants. Since 2023, France has implemented two preventive strategies aimed at reducing RSV burden: long‐acting monoclonal antibody nirsevimab and RSV vaccine for pregnant women, the latter becoming available from September 2024.
Marine Tarizzo +7 more
wiley +1 more source
Palivizumab Exposure and the Risk of Autoimmune Disease:A Cross-National Cohort Study
, 2016 BACKGROUND: Treatment with biologic pharmaceuticals may be associated with an increased risk of immune-mediated disease. Palivizumab is a humanized monoclonal antibody designed to provide passive immunity against respiratory syncytial virus infection ...
Linder, Marie +6 more
core +1 more source
Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro
The Turkish Journal of PediatricsBackground. Respiratory syncytial virus (RSV) is one of the most common pathogens causing severe lower respiratory tract disease in infancy and childhood.
Envera Lekic +5 more
doaj +1 more source
Acta Paediatrica, Volume 115, Issue 6, Page 1258-1265, June 2026.ABSTRACT Aim Respiratory syncytial virus (RSV) infection is a leading cause of paediatric hospitalisations. This study describes annual RSV‐hospitalisation burden of disease, by gestational week of delivery, age and sex among children aged 0–17 years of age in Sweden, for the period 2010/11–2021/22.
Kristian Bolin +4 more
wiley +1 more source